Press release, Helsinki, 30July 2021 at 10 AM(EEST)
Nexstim Has Received an Order for an NBT System with SmartFocus TMS froma New Customer in the United States
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that it has received a new NBT System order in the United States as it continues to expand its therapy presence.
Nexstim's NBT System with SmartFocus nTMS is highly differentiated from other currently available TMS products due to its unique and highly sophisticated 3D navigation that uses its proprietary E-field algorithm to visualize the exact location, orientation, and magnitude of the stimulation.
Mikko Karvinen, CEO of Nexstim commented: "We at Nexstim are happy to strengthen our position in the U.S. therapy market as we welcome a new clinic to our user community. This sale was made possible by our recent investments in recruiting new sales representativestoour U.S. team.With our competent team, we are in anexcellent position moving forward in further expanding our therapy presence at strategic key markets such as the U.S."
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com
About Nexstim Plc
Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
SmartFocus technology is used in Nexstim's proprietary Navigated Brain Therapy (NBT) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT system is CE marked for the treatment of major depression and chronic neuropathic pain.
In addition, Nexstim is commercializing its SmartFocus based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
For more information please visit www.nexstim.com
Attachment
- Press release_NBT Sale_30072021_Anonymous_final (https://ml-eu.globenewswire.com/Resource/Download/3995893b-6383-48c8-946c-788bb298cfd1)
